CONTINUOUS BIOPROCESSING – JUSTIFYING YOUR COMPANY’S INVEST
Continuous Bioprocessing – Justifying Your Company’s Investment Opening Remarks
The Continuous Learning Curve: Selecting the Right Products, Platforms, Equipment
Simon Hawdon (Principal Scientist, CPI’s National Biologics Manufacturing Centre) and moderator John Bonham-Carter (Vice President Business Development and Product Management, Erbi Biosystems) discuss The Continuous Learning Curve: Selecting the Right Products, Platforms, and Equipment.
A Continuous Vision to the Future of Biomanfacturing
Chris Hwang (EVP, Chief Technical Officer, Transcenta Therapeutics) and moderator John Bonham-Carter (Vice President Business Development and Product Management, Erbi Biosystems) discuss A Continuous Vision to the Future of Biomanufacturing.
Justifying the Continuous Investment
Andy Topping (VP Bioprocess and Product Development, FUJIFILM Diosynth Biotechnologies) and moderator John Bonham-Carter (Vice President Business Development and Product Management, Erbi Biosystems) discuss Justifying the Continuous Investment.
The Financial Impact of a Continuous Strategy
Joseph Shultz (VP Bioprocess and Product Development, Evelo Biosciences) and moderator John Bonham-Carter (Vice President Business Development and Product Management, Erbi Biosystems) discuss The Financial Impact of a Continuous Strategy.